- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Fut8 Sugar coating immuno oncology
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel therapy for drug-resistant cancers
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Selective JAK inhibition: mimicking SOCS activity
- Targeting minor class splicing
- Treating Epstein-Barr virus associated malignancies
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Anne Voss
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Bob Anderson
- Dr Brad Sleebs
- Dr Diana Hansen
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Ian Majewski
- Dr Jacqui Gulbis
- Dr James Vince
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kate Sutherland
- Dr Kelly Rogers
- Dr Leanne Robinson
- Dr Leigh Coultas
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Misty Jenkins
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rhys Allan
- Dr Samir Taoudi
- Dr Sant-Rayn Pasricha
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jason Tye-Din
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- 6 cysteine proteins key mediators between malaria parasites and human host
- A balancing act of immunity: autoimmunity versus malignancies
- Activating https://www.wehi.edu.au/node/add/individual-student-research-page#Parkin to treat Parkinson’s disease
- Analysing single cell technologies to understand breast cancer
- Bioinformatics methods for detecting and making sense of somatic genomic rearrangements
- Characterising new regulators in inflammatory signalling pathways
- Computational melanoma genomics
- Control of human lymphocyte cell expansion in complex immune diseases
- Deciphering biophysical changes in red blood cell membrane during malaria parasite infection
- Deciphering the signalling functions of pseudokinases
- Deep profiling of blood cancers during targeted therapy
- Determining the mechanism of type I cytokine receptor triggering
- Differential expression analysis of RNA-seq using multivariate variance modelling
- Discovering new genetic causes of primary antibody deficiencies
- Discovery of novel drug combinations for the treatment of bowel cancer
- Drug targets and compounds that block growth of malaria parasites
- Effects of nutrition on immunity and infection in Asia and Africa
- Enabling deubiquitinase drug discovery
- Epigenetic drivers of immune cell function
- Epigenetic regulation of systemic iron homeostasis
- Essential role of glycobiology in malaria parasites
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Fatal attraction: how apoptotic pore assembly is governed during mitochondrial cell death
- Genomic instability and the immune microenvironment in lung cancer
- How do T lymphocytes decide their fate?
- How the epigenetic regulator SMCHD1 works and how to target it to treat disease
- Human lung protective immunity to tuberculosis: host-environment systems biology
- Human monoclonal antibodies against malaria infection
- Identifying novel treatment options for ovarian carcinosarcoma
- Inflammasome activation in autoinflammatory disease
- Investigating mechanisms of cell death and survival using zebrafish
- Investigating microbial natural products with anti-protozoal activity
- Investigating the role of mutant p53 in cancer
- Investigating the role of platelets in motor neuron disease
- Mapping DNA repair networks in cancer
- Molecular mechanisms controlling embryonic lung progenitor cells
- Nanobodies against malaria
- Neutrophil heterogeneity in inflammation
- New approaches to treat cancer and inflammatory disease using the ubiquitin system
- Next generation CRISPR screens using iPSC
- Novel cell death and inflammatory modulators in lupus
- Programming T cells to defend against infections
- Restraining cytokine-receptor signalling in myeloproliferative neoplasms
- Screening for regulators of jumping genes
- Statistical analysis of genome-wide chromatin organisation using Hi-C
- Statistical analysis of trapped-ion-mobility time-of-flight mass spectrometry proteomics data
- Structure and function of E3 ubiquitin ligases
- The mitochondrial TOM complex in neurodegenerative disease
- The molecular mechanisms underlying Kir4.1 activity in gliomas
- The role of differential splicing in the genesis of breast cancer
- Uncovering the roles of long non-coding RNAs in human bowel cancer
- Understanding malaria infection dynamics
- Understanding the function of the E3 ligase Parkin in Parkinson’s disease
- Understanding the molecular basis of chromosome instability in gastric cancer
- Utilising pre-clinical models to discover novel therapies for tuberculosis
- School resources
- Frequently asked questions
- Student profiles
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Pancreatic cancer

Pancreatic cancer is often diagnosed at an advanced stage and few effective treatment options are available. Survival rates have remained low for the past 40 years.
Our researchers are discovering how pancreatic cancer cells become resistant to current therapies. Our goal is to find more effective treatments to improve outcomes for people with pancreatic cancer.
Pancreatic cancer research at the Institute
Our researchers are:
- Identifying new drugs to treat pancreatic cancer.
- Finding ways to overcome resistance to current therapies.
- Developing biomarkers to allow early warning of disease.
- Developing a pancreatic cancer registry to accelerate research and better understand the disease.
What is pancreatic cancer?
Pancreatic cancer is the abnormal, uncontrolled growth of epithelial cells in the pancreas.
The pancreas is an organ in the abdomen, located between the stomach and spine. It has two different types of glands:
- Exocrine glands make enzymes that break down food so it can be used by the body. The enzymes are secreted from the pancreas into the intestines.
- Endocrine glands make hormones that regulate blood sugar levels. The hormones are released directly from the pancreas into the bloodstream.
Most pancreatic cancers start in the exocrine glands.
People with pancreatic cancer usually have no obvious symptoms in the early stages, and there is currently no screening program to identify people at risk of the disease. As a result, pancreatic cancer is often not diagnosed until it is quite advanced. Pancreatic cancer is difficult to treat and only seven per cent of people survive five years after diagnosis.
What causes pancreatic cancer?
Pancreatic cancer arises through accumulation of genetic damage. Recent studies have revealed many different genetic changes in pancreatic cancer. These studies show there is a great deal of variation between individual cases of pancreatic cancer.
Understanding the genes that drive pancreatic cancer will allow more personalised treatments tailored to the particular genetic changes in each individual.
Pancreatic cancer risk factors
Some of the factors that increase a person’s risk of developing pancreatic cancer include:
- Ageing
- Smoking
- Excessive alcohol consumption
- Diabetes
- Long-term inflammation of the pancreas (chronic pancreatitis)
- Family history of pancreatic, ovarian or colon cancer
How is pancreatic cancer treated?
If pancreatic cancer is detected at an early stage it can often be treated by surgery. Chemotherapy may also be used to reduce the chance of the cancer returning. In cases where the disease is more advanced or has spread beyond the pancreas, surgery may not be effective and treatment is focused on relieving symptoms of the disease.
There is an urgent need for new therapies for pancreatic cancer. Only a handful of new drugs have been approved for the treatment of pancreatic cancer in the last decade. Current drugs only improve survival for a small proportion of people with pancreatic cancer, and only for a short time before the cancer becomes resistant to treatment.
Our researchers are using genetic analyses and human organoid cultures to identify better drugs and drug combinations for treating pancreatic cancer. We aim to improve outcomes for people with this disease.
Support for people with pancreatic cancer
Institute researchers are not able to provide specific medical advice to individuals.
For more information about how pancreatic cancer is treated and for patient support, please visit the Pancare Foundation, the Peter MacCallum Cancer Centre, Cancer Council Victoria or consult your medical specialist.
Researchers:
Super Content:
An international research team has developed a new blood test for the early detection of eight common cancers, diagnosing tumours before they have spread, when the chance of cure is high.
Lung, colorectal, pancreatic and rare cancers are on the hit list of Institute researchers who have recently received Victorian Cancer Agency grant funding.
Researchers have produced the first 3D map of a molecular structure called SgK223, known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.




